美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

KraneShares MSCI All China Health Care Index ETF

18.20

-0.0800-0.44%

成交量：1.03萬

成交額：18.84萬

市值：1.07億

市盈率：- -

高：18.28

開：18.28

低：18.20

收：18.28

52周最高：21.50

52周最低：14.38

股本：590.02萬

流通股本：590.02萬

量比：0.97

換手率：0.17%

股息：0.71

股息率：3.93%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

石藥集團(01093.HK)：SYS 6010聯合恩朗蘇拜單抗用於治療未經系統性治療的驅動基因陰性晚期NSCLC的I / II期臨床研究數據於2026年世界肺癌大會(WCLC)上以口頭報告形式公布

百濟神州員工購股計劃完成購買812,149股涉及4,590名員工

百濟神州(06160.HK)：合共6.25萬股美國存托股份由4590名參與者根據2018員工購股計劃購買

大行評級丨傑富瑞：康方生物依沃西單抗H-2研究取得正面結果，維持「買入」評級

小摩：康方生物(09926.HK)HARMONi-2總生存期數據強勁維持「增持」評級

信達生物(01801)出現大手買入6.45萬股，成交價$96.65，涉資623.392萬

阿斯达克财经

《大行》富瑞：康方生物(09926.HK)依沃西單抗單藥總生存期數據良好

阿斯达克财经

藥明生物(02269)股價上升5.021%，現價港幣$49.36

阿斯达克财经

港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化機構指回調後配置價值凸顯

港股異動 | CRO概念股漲幅居前、凱萊英大漲12%，中報持續驗證行業高景氣，多家公司上調業績指引

大行評級丨花旗：維持康方生物「買入」評級，HARMONi-2總生存期優效強化ivonescimab差異化優勢

港股早盤低開高走恒生指數半日上漲0.35% 藥明生物（02269）漲4.81%

《大行》花旗：康方生物(09926.HK)HARMONi-2總生存期優效強化ivonescimab差異化優勢

阿斯达克财经

康方生物(09926.HK)升近半成里昂：Harmoni-2總生存期更新正面

阿斯达克财经

港股異動丨康方生物漲近7%，依沃西試驗生存期超過默沙東競品

醫藥板塊表現強勢凱萊英（06821）升逾5% 機構制AI製藥商業化風口初步顯現

康方生物港股走高其依沃西單藥在試驗中的總生存期超過默沙東競品

南方财经网

康方生物(09926)出現大手賣出6.4萬股，成交價$90.0，涉資576萬

阿斯达克财经

康方生物盤初漲逾4% 依沃西對比帕博利珠單抗相關研究成果於WCLC大會重磅發布

高盛：中國CRO/CDMO行業復甦步伐明確看好藥明系等

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/KURE/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":18.2,"timestamp":1789745976154,"preClose":18.28,"halted":0,"volume":10307,"delay":0,"changeRate":-0.00437636761487975,"floatShares":5900168,"shares":5900168,"eps":0,"marketStatus":"交易中","change":-0.08,"latestTime":"09-18 11:59:27 EDT","open":18.28,"high":18.28,"low":18.2,"amount":188372.844935,"amplitude":0.004376,"askPrice":18.47,"askSize":400,"bidPrice":18.2,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789761600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":18.28,"sharesOutstanding":4750002,"nav":18,"aum":106217991.86,"dividendRate":0.039275,"bidAskSpread":0.007567,"postHourTrading":{"tag":"盘后","latestPrice":18.28,"preClose":18.28,"latestTime":"19:30 EDT","volume":9,"amount":164.52,"timestamp":1789687803600,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.974523,"impliedVol":0.1722,"impliedVolPercentile":0.3665},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5900168,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.974523,"shares":5900168,"dividePrice":0.7148,"high":18.28,"amplitude":0.004376,"preClose":18.28,"low":18.2,"week52Low":14.3797,"pbRate":"--","week52High":21.5,"institutionHeld":0,"latestPrice":18.2,"committee":-0.333333,"eps":0,"divideRate":0.039275,"volume":10307,"delay":0,"ttmEps":0,"open":18.28,"prevYearClose":17.04,"prevWeekClose":17.74,"prevMonthClose":18.54,"prevQuarterClose":15.747,"fiveDayClose":17.74,"twentyDayClose":19.34,"sixtyDayClose":15.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667269654","title":"石藥集團(01093.HK)：SYS 6010聯合恩朗蘇拜單抗用於治療未經系統性治療的驅動基因陰性晚期NSCLC的I / II期臨床研究數據於2026年世界肺癌大會(WCLC)上以口頭報告形式公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2667269654","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667269654?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:34","pubTimestamp":1789378468,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B543WZ88.USD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","LU1328277881.USD","LU1807302812.USD","IE00B5MMRT66.SGD","LU1152091168.USD","LU0067412154.USD","LU1226288170.HKD","BK1191","BK1521","LU0072913022.USD","LU0880133367.SGD","LU0314109678.HKD","BK1515","LU1813983027.USD","01093","LU1993786604.SGD","LU2039709279.SGD","LU0501845795.SGD","LU1960683339.HKD","HK0000165453.HKD","IE00BZ08YR35.GBP","LU1951186391.HKD","KURE","IE0008369823.USD","LU1226287875.USD","LU1152091754.HKD","LU0315179316.USD","IE00B031HY20.USD","LU1226287792.SGD","LU1226287529.USD","LU0140636845.USD","LU1226288253.USD","LU1008478684.HKD","IE0008368742.USD","LU0326950275.SGD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654360","title":"百濟神州員工購股計劃完成購買812,149股 涉及4,590名員工","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654360","media":"同花顺","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667654360?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:09","pubTimestamp":1789376940,"startTime":"0","endTime":"0","summary":"9月14日，百济神州(06160.HK)宣布，截至2026年8月31日认购期结束，4,590名合资格雇员根据2018员工购股计划合共购买62,473股美国存托股份，涉及股份数目为812,149股，占已发行股份总数约0.05 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260914/c679883948.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260914/c679883948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["688235","LU0307460666.USD","BK1161","LU0228659784.USD","LU1969619763.USD","ONC","LU1303224171.USD","BK1583","LU0828237510.HKD","BK4139","KURE","BK1500","LU1719994722.HKD","06160","BK4588","BK1588","LU0588546209.SGD","BK0239","BK4526","LU2328871848.SGD","LU1770034418.SGD","BK4585","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667651186","title":"百濟神州(06160.HK)：合共6.25萬股美國存托股份由4590名參與者根據2018員工購股計劃購買","url":"https://stock-news.laohu8.com/highlight/detail?id=2667651186","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667651186?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:58","pubTimestamp":1789376313,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0828237510.HKD","KURE","LU1969619763.USD","06160","LU0307460666.USD","LU1719994722.HKD","LU0228659784.USD","LU0588546209.SGD","LU1303224171.USD","LU2328871848.SGD","BK1500","BK1583","LU1770034418.SGD","BK1588","LU1251922891.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656624","title":"大行評級丨傑富瑞：康方生物依沃西單抗H-2研究取得正面結果，維持「買入」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656624","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656624?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:59","pubTimestamp":1789372758,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1794554557.SGD","LU0417516571.SGD","LU0348735423.USD","BK1574","IE00B543WZ88.USD","LU0417516738.SGD","IE00BPRC5H50.USD","09926","LU1720050803.USD","LU0348766576.USD","KURE","IE00B5MMRT66.SGD","LU0348784397.USD","LU1961090484.USD","LU2488822045.USD","LU0561508036.HKD","LU0540923850.HKD","LU0348825331.USD","LU0348827113.USD","LU0417516902.SGD","LU2476274308.USD","LU2476274720.SGD","LU2399975544.HKD","BK1161","LU0634319403.HKD","LU2778985437.USD","LU0348783233.USD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656089","title":"小摩：康方生物(09926.HK)HARMONi-2總生存期數據強勁 維持「增持」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656089","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656089?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:38","pubTimestamp":1789371481,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0634319403.HKD","LU1720050803.USD","IE00B5MMRT66.SGD","LU2399975544.HKD","LU2476274720.SGD","LU0348766576.USD","LU0348783233.USD","LU2778985437.USD","09926","LU0348735423.USD","KURE","LU2488822045.USD","LU1961090484.USD","LU0540923850.HKD","BK1574","IE00B543WZ88.USD","LU0561508036.HKD","LU0348767384.USD","LU1794554557.SGD","LU0417516738.SGD","BK1161","LU0348827113.USD","LU0417516902.SGD","LU0417516571.SGD","IE00BPRC5H50.USD","LU2476274308.USD","LU0348784397.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667665575","title":"信達生物(01801)出現大手買入6.45萬股，成交價$96.65，涉資623.392萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2667665575","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667665575?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:19","pubTimestamp":1789370340,"startTime":"0","endTime":"0","summary":"[大手成交]信达生物(01801)在下午03:19出现大手买入，成交量为6.45万，成交价为港币$96.65，涉资623.392万。至目前为止，股价升3.26%，今日最高价为$97.4，而最低价为$91.7，总成交量为919.039万股，总成交金额港币$8.763亿。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609144731/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609144731/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1188198961.HKD","LU0244354667.USD","LU2097828557.USD","LU2097828631.EUR","LU0463099449.HKD","LU1969619763.USD","HK0000165453.HKD","LU0607220059.USD","01801","LU1831875114.USD","LU0326950275.SGD","BK1589","BK1583","LU2097828714.EUR","LU0149534421.HKD","LU2328871848.SGD","LU0455707207.USD","LU0502904849.HKD","LU2488822045.USD","BK1161","LU2097828474.EUR","KURE","LU2242644610.SGD","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667655595","title":"《大行》富瑞：康方生物(09926.HK)依沃西單抗單藥總生存期數據良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2667655595","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667655595?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:06","pubTimestamp":1789369560,"startTime":"0","endTime":"0","summary":"富瑞发表研究报告指，康方生物(09926.HK) 依沃西单抗(Ivonescimab)H-2研究取得正面结果，数据显示，其中期总生存期(OS)具统计学显著性，单药一线治疗PD-L1阳性非小细胞肺癌较帕博利珠单抗(Pembrolizumab)OS显著延长，OS中位数为30.8个月，风险比为0.73，中位随访36个月，对比帕博利珠单抗OS中位数为22.6个月。富瑞指出，康方生物依沃西单抗拥有总生存期优势，数据令人鼓舞，维持“买入”评级及目标价226元。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-14 12:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200424093930528_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200424093930528_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544311/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544311/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0348783233.USD","LU2399975544.HKD","LU0417516738.SGD","LU1720050803.USD","LU2488822045.USD","LU0561508036.HKD","LU1794554557.SGD","IE00B5MMRT66.SGD","LU0348784397.USD","LU0634319403.HKD","LU0348825331.USD","LU0540923850.HKD","LU0348827113.USD","LU0348735423.USD","09926","BK1161","KURE","LU0348767384.USD","IE00BPRC5H50.USD","LU0417516902.SGD","BK1574","LU2476274308.USD","LU1961090484.USD","LU0348766576.USD","LU0417516571.SGD","LU2476274720.SGD","LU2778985437.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667342658","title":"藥明生物(02269)股價上升5.021%，現價港幣$49.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2667342658","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667342658?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:04","pubTimestamp":1789365840,"startTime":"0","endTime":"0","summary":"[上升股]药明生物(02269) 股价在下午02:03比前收市价上升5.021%，现股价为港币$49.36。至目前为止，今日最高价为$49.36，而最低价为$46.42。总成交量为2.124千万股，总成交金额为港币$10.284亿。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609141471/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609141471/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0856984785.SGD","LU0588546209.SGD","LU1720050803.USD","LU0516423091.SGD","LU0307460666.USD","LU0348735423.USD","SG9999002463.SGD","LU0823426480.USD","LU0359201612.USD","LU3063872942.SGD","LU0819121731.USD","LU0708995583.HKD","LU0516422366.SGD","LU0456846285.SGD","LU1242518857.USD","LU0051755006.USD","LU0516423174.USD","LU0348827113.USD","BK1521","LU1688375341.USD","LU0320764599.SGD","LU0823426308.USD","BK1610","LU0456827905.SGD","LU0029874061.USD","LU1242518931.SGD","LU0417516738.SGD","LU0128526141.USD","LU0516422440.USD","LU2039709279.SGD","LU0326950275.SGD","LU0327786744.USD","LU0561508036.HKD","LU1794554557.SGD","LU0516422952.EUR","LU0181495838.USD","IE00B0JY6N72.USD","LU0979878070.USD","LU0572944931.SGD","LU0039217434.USD","BK1589","BK1141","02269","LU0417516902.SGD","LU0359202008.SGD","LU1880383366.USD","KURE","LU0043850808.USD","LU0140636845.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608630","title":"港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化 機構指回調後配置價值凸顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667608630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:39","pubTimestamp":1789364389,"startTime":"0","endTime":"0","summary":"消息面上，9月12-15日，2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3ADC等成为焦点。中泰证券指出，WCLC集中披露的多项肺癌领域临床进展，进一步验证了中国创新药的临床价值和全球竞争力，或可积极把握创新药回调后的配置机会。机构普遍认为，三季度部分企业新增订单进入收入确认期，基本面有望持续改善。当前医药板块估值27倍PE，低于历史均值，回调后配置价值凸显。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0634319403.HKD","LU0348784397.USD","LU0348767384.USD","09969","LU2488822045.USD","LU0348735423.USD","LU1188198961.HKD","BK1593","LU0455707207.USD","LU2097828557.USD","LU0607220059.USD","IE00BZ08YR35.GBP","01801","LU0348827113.USD","BK1521","MEDX","LU2097828714.EUR","LU0348766576.USD","LU0417516571.SGD","LU1831875114.USD","IE00B543WZ88.USD","LU2242644610.SGD","LU2778985437.USD","LU2476274720.SGD","LU1969619763.USD","LU2476274308.USD","KCAI","01530","LU0417516738.SGD","LU0326950275.SGD","IE00BPRC5H50.USD","LU0561508036.HKD","HK0000165453.HKD","LU0348825331.USD","159992","LNGR","BK1589","LU2097828805.USD","01177","IBBQ","BK1574","09926","LU0244354667.USD","KURE","LU1961090484.USD","VXUS","06978","BK1191","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667763172","title":"港股異動 | CRO概念股漲幅居前、凱萊英大漲12%，中報持續驗證行業高景氣，多家公司上調業績指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2667763172","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667763172?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:34","pubTimestamp":1789364090,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股涨幅居前，截至发稿，凯莱英涨5.89%，报142.1港元；康龙化成涨4.72%，报28.84港元；泰格医药涨4.64%，报43.32港元；药明生物涨2.30%，报48.08港元。消息面上，国内外CXO公司中报业绩持续验证行业高景气。国内药明康德发布中报，业绩大幅超市场预期，同时大幅上调全年业绩指引。该行表示，看好药明系、康龙化成、凯莱英、泰格医药及金斯瑞。","market":"sh","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495468.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | CRO概念股涨幅居前，中报持续验证行业高景气，多家公司上调业绩指引","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0456846285.SGD","BK1521","LU0456827905.SGD","LU0856984785.SGD","LU0307460666.USD","LU0823426308.USD","LU0348827113.USD","LU0029874061.USD","LU1880383366.USD","06821","KCAI","LU0823426480.USD","LU0516423174.USD","LU1688375341.USD","LU0516422952.EUR","LU0320764599.SGD","LU0516422366.SGD","KURE","LU1720050803.USD","LU3063872942.SGD","LU0039217434.USD","LU0051755006.USD","LU0326950275.SGD","LU0128526141.USD","LU0516423091.SGD","BK1610","LU0588546209.SGD","LU0572944931.SGD","03347","LU0417516738.SGD","BK1191","LU0140636845.USD","LU0348735423.USD","LU0348825331.USD","BK4588","LU2039709279.SGD","02269","LU0359201612.USD","VXUS","SG9999002463.SGD","LU0561508036.HKD","LU0819121731.USD","LU0979878070.USD","BK1589","BK1141","BK1583","LU0359202008.SGD","LU0181495838.USD","03759","LU0327786744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637732","title":"大行評級丨花旗：維持康方生物「買入」評級，HARMONi-2總生存期優效強化ivonescimab差異化優勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637732","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667637732?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:24","pubTimestamp":1789363448,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2399975544.HKD","BK1161","LU0417516902.SGD","LU2476274720.SGD","LU0348783233.USD","KURE","LU0348766576.USD","LU1794554557.SGD","LU1961090484.USD","LU0417516738.SGD","09926","LU0348735423.USD","LU0348784397.USD","LU0417516571.SGD","LU1720050803.USD","LU2488822045.USD","LU0348825331.USD","LU0348767384.USD","LU2476274308.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0348827113.USD","LU0561508036.HKD","LU0540923850.HKD","LU0634319403.HKD","BK1574","LU2778985437.USD","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667378766","title":"港股早盤低開高走 恒生指數半日上漲0.35% 藥明生物（02269）漲4.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667378766","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667378766?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 12:18","pubTimestamp":1789359482,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股早盘低开高走，截至午间收盘，恒生指数上涨0.35%；国企指数上涨0.4%，恒生科技指数上涨0.17%。医药概念板块表现强势，凯莱英涨10.88%，康龙化成涨5.15%，泰格医药涨7%，药明康德涨4.61%，药明生物涨4.81%。个股方面，联想集团股价扬升，半日涨4.6%。在中国x86服务器市场，第二季度，联想的x86服务器营收同比增长9.0%，以10.5%的市场份额排名第四。长风药业股价冲高回落，半日涨1.16%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/MTYwMGM1ZDEwYjRjZDY4ZmI3MTk0ZDEyM2Y1MWFkMjMxODA4Mzk0Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MTYwMGM1ZDEwYjRjZDY4ZmI3MTk0ZDEyM2Y1MWFkMjMxODA4Mzk0Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991494","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0048580855.USD","02652","LU0856984785.SGD","LU1880383366.USD","LU0370786039.SGD","LU0979878070.USD","LU1242518857.USD","LU0039217434.USD","LU0708995583.HKD","LU0456827905.SGD","BK1191","BK1589","03037","BK1576","LU1808992512.USD","LU0049112450.USD","LU0348735423.USD","WXXWY","07300","LU1785774172.SGD","09115","LU1366334651.USD","BK1141","BK1193","LU0561508036.HKD","SG9999002463.SGD","HHImain","00992","80992","MCHmain","LU1366334578.USD","LU1794554557.SGD","LU0543330483.HKD","BK1610","LU0320764599.SGD","LU1267930227.SGD","07200","LU1235295612.USD","IE0032431581.USD","LU0348825331.USD","LU0516423091.SGD","LU0326950275.SGD","LU0359201612.USD","LU0572939691.SGD","LU0043850808.USD","07500","LU1688375341.USD","513600","HK0000306685.HKD","BK1607","LU0359202008.SGD","LU0417516738.SGD","HK0000320223.HKD","LU0823426480.USD","LU0672654166.SGD","BK1521","BK1526","LU0791591158.USD","LU0862451837.USD","LU0029875118.USD","LU0128526141.USD","LU0516422952.EUR","LU0307460666.USD","LU2242644610.SGD","LU0572944931.SGD","HK0000306701.USD","LU0456846285.SGD","LU0862451753.SGD","LU0890818403.SGD","LU0972618739.USD","SG9999002562.SGD","LU0516422440.USD","LU0320764755.SGD","IE00B0JY6N72.USD","LU0310800965.SGD","KURE","82800","LU3063872942.SGD","LU0052750758.USD","HSI","IE0003895053.USD","LU0327786744.USD","IE0034224299.USD","LU1242518931.SGD","LU0128522157.USD","LU2039709279.SGD","LU0140636845.USD","LU0819121731.USD","LU0051755006.USD","03115","LU0348827113.USD","LU0052756011.USD","LU0791590937.USD","HK0000320264.USD","LU0128525689.USD","LU1720050803.USD","83115","LU0181495838.USD","02833","LU0572940350.SGD","LU0516423174.USD","02269","02800","HSTECH","LU1046422090.SGD","LU0417516902.SGD","LU0264606111.USD","LU0588546209.SGD","LU0029874061.USD","LU0516422366.SGD","TCHI","03419","LNVGY","LU0823426308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632069","title":"《大行》花旗：康方生物(09926.HK)HARMONi-2總生存期優效強化ivonescimab差異化優勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632069","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632069?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 12:14","pubTimestamp":1789359240,"startTime":"0","endTime":"0","summary":"花旗发表研究报告指，康方生物的HARMONi-2中期读数显示，ivonescimab作为PD-L1阳性非小细胞肺癌一线单药治疗，对比pembrolizumab展现有意义的总生存期优效，强化其差异化定位，全球读数仍是关键。该行指出，HARMONi-2在234宗总生存期事件下，ivonescimab的中位总生存期为30.75个月；总生存期获益在PD-L1 TPS > 50%及鳞状非小细胞肺癌，整体存活期获益最为明显，安全性大致相若。该行维持康方生物“买入”评级，目标价171港元不变。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200914151046636_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200914151046636_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544280/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544280/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["IE00BPRC5H50.USD","LU1961090484.USD","LU0348825331.USD","LU0348784397.USD","LU0348783233.USD","LU2476274308.USD","LU2476274720.SGD","LU0417516902.SGD","BK1574","LU1794554557.SGD","LU0561508036.HKD","IE00B543WZ88.USD","LU0348767384.USD","09926","LU0348827113.USD","LU2488822045.USD","LU2778985437.USD","IE00B5MMRT66.SGD","LU0348766576.USD","LU0540923850.HKD","LU1720050803.USD","LU0417516738.SGD","LU2399975544.HKD","LU0348735423.USD","LU0634319403.HKD","LU0417516571.SGD","KURE","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632490","title":"康方生物(09926.HK)升近半成  里昂：Harmoni-2總生存期更新正面","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632490","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632490?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:57","pubTimestamp":1789358220,"startTime":"0","endTime":"0","summary":"康方生物今日高开4.49%，最高见96.55元。里昂发表研究报告指，康方生物公布Harmoni-2正面总生存期更新，ivonescimab录得中位OS 30.75个月，对比pembrolizumab 22.57个月，风险比为0.73，显示具统计学意义及临床意义的生存获益。该行认为，该药OS结果符合投资者预期，并为医生提供更多ivonescimab临床表现优于pembrolizumab的证据，尽管风险比不及Harmoni-6的0.66更新吸引；OS数据亦较2025年4月中国标签更新时风险比0.78有所改善。Harmoni-3无进展生存期读出，以及美国FDA于今年下半年就ivonescimab的决定，为后续关键催化剂。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544272/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544272/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0417516571.SGD","LU0348827113.USD","LU0348767384.USD","LU2399975544.HKD","IE00BPRC5H50.USD","LU2778985437.USD","LU0348783233.USD","LU0348784397.USD","LU1794554557.SGD","LU0634319403.HKD","LU0348825331.USD","LU0417516738.SGD","LU2488822045.USD","IE00B5MMRT66.SGD","09926","BK1161","LU0561508036.HKD","BK1574","KURE","LU1720050803.USD","LU0348766576.USD","LU2476274720.SGD","IE00B543WZ88.USD","LU0417516902.SGD","LU2476274308.USD","LU0540923850.HKD","LU0348735423.USD","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632842","title":"港股異動丨康方生物漲近7%，依沃西試驗生存期超過默沙東競品","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632842","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632842?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:33","pubTimestamp":1789356838,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0634319403.HKD","LU1720050803.USD","IE00B5MMRT66.SGD","LU2399975544.HKD","LU2476274720.SGD","LU0348766576.USD","LU0348783233.USD","LU2778985437.USD","09926","LU0348735423.USD","KURE","LU2488822045.USD","LU1961090484.USD","LU0540923850.HKD","BK1574","IE00B543WZ88.USD","LU0561508036.HKD","LU0348767384.USD","LU1794554557.SGD","LU0417516738.SGD","BK1161","LU0348827113.USD","LU0417516902.SGD","LU0417516571.SGD","IE00BPRC5H50.USD","LU2476274308.USD","LU0348784397.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667083631","title":"醫藥板塊表現強勢 凱萊英（06821）升逾5% 機構制AI製藥商業化風口初步顯現","url":"https://stock-news.laohu8.com/highlight/detail?id=2667083631","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667083631?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 10:26","pubTimestamp":1789352818,"startTime":"0","endTime":"0","summary":"消息面上，招商证券指出，自2024年以来，AI制药发展速度明显加快，投资规模和项目数量显著增长。跨国药企开始大规模搭建自有AI平台能力，合作模式由单点项目合作转向管线与平台层面深度合作。AI科技巨头入局药物研发领域，依托通用大模型推出面向药物研发的专用AI模型。AI Biotech的合作机会与交易规模持续扩容，即便尚未拥有成熟商业化管线，也获得传统药企青睐。AI制药行业已完成概念验证，正式迈入临床验证阶段，商业化风口初步显现。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991473","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","LU0128526141.USD","LU2242644610.SGD","CHAT","LU0359201612.USD","06821","LU0819121731.USD","02269","LU1328615791.USD","LU1720050803.USD","02359","159938","LU0307460666.USD","SG9999002463.SGD","QTOC","LU0979878070.USD","LU1046422090.SGD","BK1583","LU0326950275.SGD","LU0823426480.USD","LU0417516902.SGD","ARTY","BK1610","BK1515","LU1688375341.USD","LU0043850808.USD","LU0516422366.SGD","LU0417516738.SGD","VTHR","LU0052750758.USD","SG9999002562.SGD","KURE","002821","AIPO","LU0588546209.SGD","LU1242518857.USD","LU2125910500.SGD","03347","BK1141","LU1242518931.SGD","LU1880383366.USD","IE00B0JY6N72.USD","BK0239","LU0348766576.USD","LU0516423174.USD","BK1191","01477","03759","AGIX","LU0516422440.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667463107","title":"康方生物港股走高 其依沃西單藥在試驗中的總生存期超過默沙東競品","url":"https://stock-news.laohu8.com/highlight/detail?id=2667463107","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667463107?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 10:16","pubTimestamp":1789352160,"startTime":"0","endTime":"0","summary":"南方财经9月14日电，康方生物港股盘初一度上涨5.8%，随后收窄涨幅。此前公司宣布，对比默沙东公司的帕博利珠单抗，其肿瘤免疫药物依沃西显著延长了中位总生存期(OS)至30.8个月，而前者为22.6个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873200884.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873200884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0634319403.HKD","LU0348784397.USD","LU1720050803.USD","LU0348767384.USD","LU2488822045.USD","LU0348735423.USD","BK1161","LU0540923850.HKD","BK4585","LU0348783233.USD","LU0348827113.USD","LU0348766576.USD","LU0417516571.SGD","IE00B543WZ88.USD","LU2778985437.USD","LU2476274720.SGD","LU2476274308.USD","KCAI","LU0417516738.SGD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU0561508036.HKD","LU1794554557.SGD","LU2399975544.HKD","LU0417516902.SGD","BK1574","09926","LU1961090484.USD","KURE","VXUS","BK4588","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667863165","title":"康方生物(09926)出現大手賣出6.4萬股，成交價$90.0，涉資576萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2667863165","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667863165?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:45","pubTimestamp":1789350300,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在上午09:45出现大手卖出，成交量为6.4万，成交价为港币$90.0，涉资576万。至目前为止，股价跌0.166%，今日最高价为$95.5，而最低价为$90.0，总成交量为364.9万股，总成交金额港币$3.343亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609142177/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609142177/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1794554557.SGD","LU0348783233.USD","LU0348827113.USD","BK1574","LU0417516738.SGD","LU1961090484.USD","KURE","IE00B543WZ88.USD","LU0348767384.USD","LU2476274720.SGD","LU0417516571.SGD","LU2476274308.USD","LU1720050803.USD","LU2488822045.USD","IE00BPRC5H50.USD","LU2778985437.USD","LU0348825331.USD","BK1161","IE00B5MMRT66.SGD","09926","LU0348766576.USD","LU0634319403.HKD","LU0561508036.HKD","LU0348735423.USD","LU0540923850.HKD","LU0417516902.SGD","LU0348784397.USD","LU2399975544.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631397","title":"康方生物盤初漲逾4% 依沃西對比帕博利珠單抗相關研究成果於WCLC大會重磅發布","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631397","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667631397?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:44","pubTimestamp":1789350240,"startTime":"0","endTime":"0","summary":"据康方生物官微消息，在国际肺癌研究协会主办的2026年世界肺癌大会上，公司全球首创肿瘤免疫2.0基石药物依沃西，对比帕博利珠单抗，一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的随机、双盲、对照、多中心、注册性III期临床研究的OS显著阳性结果重磅发布。截至目前，依沃西在多项头对头对比PD-1/L1疗法的III期临床中取得OS和PFS双阳性结果，并逐步拓展至肺癌以外的重大实体瘤领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-14/doc-iniruara9666421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BPRC5H50.USD","LU2488822045.USD","LU2778985437.USD","LU0540923850.HKD","LU0561508036.HKD","LU0348784397.USD","KURE","LU1720050803.USD","09926","LU1794554557.SGD","LU0634319403.HKD","LU0348767384.USD","LU0348783233.USD","LU0348827113.USD","LU2399975544.HKD","LU0417516738.SGD","LU2476274720.SGD","LU2476274308.USD","LU0348766576.USD","IE00B543WZ88.USD","LU1961090484.USD","LU0348825331.USD","LU0348735423.USD","IE00B5MMRT66.SGD","BK1574","BK1161","LU0417516902.SGD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667318226","title":"高盛：中國CRO/CDMO行業復甦步伐明確 看好藥明系等","url":"https://stock-news.laohu8.com/highlight/detail?id=2667318226","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667318226?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:38","pubTimestamp":1789349915,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，今年第二季度及上半年业绩反映中国CRO/CDMO行业正明确复苏，企业盈利超出预期、上调指引及订单强劲。该行对药明康德、药明合联、凯莱英、康龙化成给予“买入”评级。高盛指出，生物科技公司上半年盈利转正，BD收入及运营杠杆亦获支持，吸引投资者目光，加上市场对反腐行动的担忧有所缓解。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CDMO","LU0348825331.USD","LU0417516738.SGD","LU0979878070.USD","02268","LU0463099449.HKD","LU1791807156.HKD","LU1868837300.USD","IE0004091025.USD","LU0516422440.USD","LU0051755006.USD","LU0359202008.SGD","LU2471134879.HKD","02269","LU0029874061.USD","BK1576","LU0823426308.USD","LU1880383366.USD","LU0561508036.HKD","03759","LU0516422366.SGD","LU2265009873.SGD","LU1894683348.USD","LU1668664300.SGD","KURE","LU0345770308.USD","LU0823426480.USD","LU1144417596.USD","LU2471134523.USD","03347","LU2471134952.CNY","02359","LU0456846285.SGD","LU0516423174.USD","LU3063872942.SGD","LU0856984785.SGD","LU0061475181.USD","GSX","06821","IE00BFXG1179.USD","LU0942090050.USD","LU2039709279.SGD","LU2045819591.USD","LU1242518931.SGD","LU0868494617.USD","LU0251142724.SGD","LU0210536198.USD","LU0043850808.USD","LU0359201612.USD","BK1610"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}